Previously recorded as Trovagene, Inc. (to 2020)
10 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Oct 2027
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2028 · High confidence
Also notable
Ends Oct 2027 · High confidence
Also notable
Ends Sep 2043 · Medium confidence
Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media
US 9,163,229
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2028.
Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
US 8,501,924
The largest patent family in this portfolio, 8 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.
PLK1 Inhibitor in Combination with Anti-Angiogenics for Treating Metastatic Cancer
US 12,606,616
A family of 13 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2043. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 20, 2027The maintenance fee for Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media (US 9,163,229) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Cancer Treatment Using FGFR Inhibitors and PLK1 Inhibitors (US 11,957,677) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| PLK1 Inhibitor in Combination with Anti-Angiogenics for Treating Metastatic Cancer | 3 in force | to Sep 2043 |
| Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media | 2 in force | to Jul 2028 |
| Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof | 2 in force | to Mar 2028 |
| Predictive Biomarkers for Onvansertib Treatment | 1 in force | to Nov 2044 |
| PLK1 Target Phosphorylation Status and Treatment of Cancer with PLK1 Inhibitors | 1 in force | to Nov 2042 |
| Cancer Treatment Using FGFR Inhibitors and PLK1 Inhibitors | 1 in force | to Oct 2042 |
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,501,924 | Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof In force · High confidence | In force | High confidence | |
| US 9,909,118 | Compositions, Methods and Kits for Isolating Nucleic Acids from Body Fluids Using Anion Exchange Media In force · High confidence | In force | High confidence | |
| US 8,222,370 | Nucleophosmin Protein (NPM) Mutants, Corresponding Gene Sequences and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,163,229 | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media In force · High confidence | In force | High confidence | |
| US 11,957,677 | Cancer Treatment Using FGFR Inhibitors and PLK1 Inhibitors In force · High confidence | In force | High confidence | |
| US 12,655,462 | PLK1 Target Phosphorylation Status and Treatment of Cancer with PLK1 Inhibitors In force · High confidence | In force | High confidence | |
| US 12,144,813 | PLK1 Inhibitor in Combination with Anti-Angiogenics for Treating Metastatic Cancer In force · Low confidence | In force | Low confidence | |
| US 12,263,173 | PLK1 Inhibitor in Combination with Anti-Angiogenics for Treating Metastatic Cancer In force · Low confidence | In force | Low confidence | |
| US 12,606,616 | PLK1 Inhibitor in Combination with Anti-Angiogenics for Treating Metastatic Cancer In force · Medium confidence | In force | Medium confidence | |
| US 12,637,718 | Predictive Biomarkers for Onvansertib Treatment In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 7 patents ended · 25 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.